cover
Contact Name
Veri Hardinansyah Dja'far
Contact Email
admin@transpublika.co.id
Phone
+6281234560500
Journal Mail Official
admin@transpublika.co.id
Editorial Address
Jl. Kolonel Sugiono IIIC/438 RT 10/RW 04 Mergosono, , Malang, Provinsi Jawa Timur, 65134
Location
Kota malang,
Jawa timur
INDONESIA
PHARMACOLOGY, MEDICAL REPORTS, ORTHOPEDIC, AND ILLNESS DETAILS (COMORBID)
Published by Transpublika Publisher
ISSN : -     EISSN : 28099745     DOI : https://doi.org/10.55047/comorbid
Core Subject : Health, Science,
About the Journal PHARMACOLOGY, MEDICAL REPORTS, ORTHOPEDIC, AND ILLNESS DETAILS (COMORBID) is an international, modern, general medical publication that publishes research on all aspects of medicine, from fundamental research to significant clinical trials and cost-effectiveness analyses. We generally publish human research that contribute to our understanding of medical epidemiology, etiology, and physiology; the development of prognostic and diagnostic technologies; clinical trials that evaluate the efficacy of particular therapies and comparative trials; and systematic reviews. We want to encourage the conversion of fundamental research into clinical trials and clinical evidence into therapeutic practice. When studies in animal models produce remarkable research findings that are extremely clinically relevant, we publish them on occasion. The international medical community, as well as educators, policymakers, patient advocacy groups, and other interested parties, are among our target audiences. The online edition of COMORBID is updated on a regular basis. Medical Informatics, Basic Science, Clinical Science, Case Report, Brief Communication, Public Health, Public Policy, and Review Articles from all branches of medicine and associated subjects are published in PHARMACOLOGY, MEDICAL REPORTS, ORTHOPEDIC, AND ILLNESS DETAILS (COMORBID)
Articles 101 Documents
Comparison of LI-RADS Scores Before and After Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma Patients Taufik Rahman; Hartono Yudi Sarastika; Widiana Ferriastuti
PHARMACOLOGY, MEDICAL REPORTS, ORTHOPEDIC, AND ILLNESS DETAILS Vol. 5 No. 3 (2026): JULY
Publisher : Transpublika Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55047/comorbid.v5i3.2163

Abstract

Hepatocellular carcinoma (HCC) is the most frequent primary liver malignancy, notorious for its elevated mortality. In intermediate-stage HCC where surgical resection is contraindicated, transarterial chemoembolization (TACE) is the primary treatment modality. Accurate evaluation of therapeutic response is essential to guide ongoing patient management. The Liver Imaging Reporting and Data System (LI-RADS), particularly its Treatment Response (LI-RADS TR) criteria, provides a validated radiographic method for assessing lesions before and after locoregional interventions. This study compared LI-RADS scores before and after TACE in patients at Dr. Soetomo Regional General Hospital, Surabaya. A retrospective observational design was employed, involving 37 HCC patients who underwent TACE and abdominal CT between January 2024 and July 2025. Statistical analysis used the paired t-test or Wilcoxon test (p < 0.05). The majority of patients were male (67.6%) with a mean age of 55.3 years. Before TACE, the most common categories were LR-5 (51.4%) and LR-4 (48.6%). Following TACE, 78.4% of tumors were classified as viable and 21.6% as non-viable by LI-RADS TR. No significant difference in tumor size was observed, but tumor-to-liver ratio was significantly reduced (p < 0.001). No significant association was identified between pre-TACE LI-RADS characteristics and post-TACE LI-RADS TR categories, except for the pre-treatment tumor-to-liver ratio. TACE significantly reduced the tumor-to-liver ratio; however, most lesions remained viable by LI-RADS TR. LI-RADS and LI-RADS TR are important tools for evaluating treatment response and guiding further management in HCC patients.

Page 11 of 11 | Total Record : 101